fbpx

Myeloproliferative Neoplasms

Nurse and patient

Examining Long-Term Outcomes With Different Imatinib Dose Levels in CML

The prospective, randomized SPIRIT trial, conducted in France, compared long-term outcomes with imatinib and imatinib combinations in patients with chronic-phase chronic myeloid leukemia (CML)....
Hand with IV Drip Receiving Medical Treatment

Study Finds “Surprisingly” High Four-Year Mortality Rate in Polycythemia Vera Patients

In results from the prospective, observational REVEAL trial, researchers described the survival rates and causes of death among patients with polycythemia vera (PV). Lead...
Shot of a group of medical practitioners having a discussion in a hospital

Oral Azacitidine Reduces Transfusion Dependence in Low-Risk MDS

Compared with placebo, treatment with CC-486, the oral formulation of the hypomethylating agent (HMA) azacitidine significantly improved red blood cell (RBC) transfusion independence in...
Macro shot of pastel pink oval shaped pills on white background with free space for text and design

Breast Cancer Drug Palbociclib Shows Promise in Myelofibrosis

Palbociclib, a drug approved to treat HR-positive and HER2-negative breast cancer, could lead to improvement in symptoms of myelofibrosis when combined with the JAK2...
doctor sitting next to an elderly patient and explaining medical documents

Study Examines Cerebral Venous Thrombosis in Patients With MPNs

In a case series published in the American Journal of Hematology, authors evaluated the relationship between myeloproliferative neoplasms (MPNs) and cerebral venous thrombosis (CVT)....
Shot of a group of medical practitioners having a discussion in a hospital

Pevonedistat Plus Azacitidine Shows Clinical Efficacy in Higher-Risk MDS and Low-Blast AML

Results from a randomized, proof-of-concept, phase II study demonstrated promising overall survival (OS), event-free survival (EFS), and overall response rates (ORR) in patients with...

Comparing 5-Azacitidine Versus Transplant in Older Patients With MDS

In a prospective multicenter study, older patients with myelodysplastic syndromes (MDS) who underwent reduced-intensity allogeneic hematopoietic stem cell transplantation (alloHSCT) had longer event-free survival...
Advertisement

Journal Reading List

Advertisement
Advertisement